Daily Respiratory Research Analysis
Analyzed 127 papers and selected 3 impactful papers.
Summary
A national implementation analysis of England’s lung cancer screening program showed large-scale feasibility, early-stage shift (63% stage I), and equity gains, while highlighting participation gaps. A randomized trial in Kyrgyzstan demonstrated that pulmonary rehabilitation for post-tuberculosis lung disease markedly improves exercise capacity and quality of life with favorable cost-effectiveness. A patient-level meta-analysis refined risk stratification for interstitial lung abnormalities, showing age drives prevalence while fibrotic features drive progression.
Research Themes
- Population-scale implementation of lung cancer screening
- Pulmonary rehabilitation for post-tuberculosis lung disease
- Natural history and progression risk of interstitial lung abnormalities
Selected Articles
1. Implementation of the NHS England Lung Cancer Screening Programme over 5 years.
Over five years, England’s LDCT program invited over two million people and diagnosed 7,193 lung cancers, with 63.1% at stage I and 12.6% at stage II. The program increased early-stage detection, particularly in socioeconomically deprived regions, while emphasizing the need to reduce participation inequalities to maximize impact.
Impact: This is one of the first national-scale, real-world demonstrations that LDCT screening can be implemented rapidly with substantial stage shift at diagnosis and equity-sensitive delivery.
Clinical Implications: Health systems can adopt centralized protocols and regional delivery to scale LDCT screening, prioritize outreach to underserved populations, and monitor early-stage detection as a quality indicator.
Key Findings
- Over two million invitations issued with 7,193 lung cancers diagnosed by March 2025.
- 63.1% stage I and 12.6% stage II at diagnosis, indicating a substantial stage shift.
- Early-stage proportion increased nationally, with notable gains in socioeconomically deprived regions; participation inequalities remain.
Methodological Strengths
- Nationwide, programmatic real-world dataset with standardized protocols.
- Clear outcome metrics including stage distribution and regional analyses.
Limitations
- Observational program evaluation without randomized comparators.
- Long-term mortality and cost-effectiveness outcomes not yet fully reported.
Future Directions: Evaluate long-term mortality reduction and cost-effectiveness, optimize risk models, and test targeted strategies to improve participation in underserved groups.
Lung cancer screening with low-dose computed tomography has been proven to reduce lung-cancer-specific and all-cause mortality. The UK launched the NHS England Targeted Lung Health Check Programme in 2019, which has now become the national Lung Cancer Screening Programme, with full coverage expected by 2030. Here we present the progress and outcomes of the program. People aged 55-74 were offered low-dose computed tomography of the thorax if they had ever smoked and if risk thresholds, as deter
2. Clinical and cost-effectiveness of pulmonary rehabilitation for people with post-tuberculosis lung disease in Kyrgyzstan: A Single-blind Randomized Controlled Trial.
Among 114 adults with PTLD, supervised pulmonary rehabilitation significantly improved maximal exercise capacity versus usual care (ISWT +123 m; 95% CI 81–165; P<0.001) and increased EQ-5D-5L VAS by 20.2 points. The intervention gained QALYs at low cost, with a purchasing-power–adjusted ~$2,143 per QALY.
Impact: This pragmatic RCT provides rare, high-quality evidence for pulmonary rehabilitation in PTLD, demonstrating clinically meaningful gains and affordability in a low-resource setting.
Clinical Implications: Pulmonary rehabilitation should be offered to PTLD patients as part of routine care, with scalable, culturally adapted programs prioritized in TB-endemic, resource-limited settings.
Key Findings
- ISWT improved by 123 m (95% CI 81.2–164.8; P<0.001) in the rehabilitation group vs. usual care.
- Health-related quality of life improved (EQ-5D-5L VAS +20.2; P<0.0001).
- Cost-effectiveness: program cost about $2,143 per QALY (purchasing power–adjusted).
Methodological Strengths
- Randomized, single-blind design with intention-to-treat analysis.
- Integrated economic evaluation alongside clinical outcomes.
Limitations
- Single-country trial with 6-week primary endpoint; durability beyond intervention period not fully established.
- Blinding limited to outcome assessors; performance bias possible.
Future Directions: Test longer-term maintenance strategies, implementation at scale, and integration with post-TB care pathways across diverse health systems.
RATIONALE: Tuberculosis (TB) is a major worldwide cause of disability, with TB survivors experiencing significant and often under-recognised burden, and approximately half going on to develop post-tuberculosis lung disease (PTLD). Pulmonary rehabilitation may offer effective disease management but there is a lack of evidence in PTLD populations. OBJECTIVES: We aimed to determine the clinical and cost effectiveness of pulmonary rehabilitation for adults living with PTLD in Kyrgyzstan. METHODS: A single-
3. Age, sex, smoking-specific prevalence and progression in interstitial lung abnormality: patient-level meta-analysis.
Across 31,739 subjects in 14 studies, pooled ILA prevalence was 5.6% and increased from 2.5% (<55 years) to 14.6% (≥80 years), amplified in males and heavy smokers. Overall progression was 34%, predominantly driven by fibrotic ILAs; age did not influence progression once ILA was present. Estimated PFS was 76% at 3 years and 55% at 5 years.
Impact: Provides patient-level, global evidence clarifying who has ILA and who progresses, shifting follow-up decisions from age to fibrotic burden and improving precision in surveillance.
Clinical Implications: Screening yield is highest in older adults, men, and heavy smokers, but follow-up intensity should be tailored to fibrotic features rather than age alone.
Key Findings
- Pooled ILA prevalence 5.6%, rising from 2.5% (<55y) to 14.6% (≥80y); higher in males and heavy smokers.
- Overall progression 34%, with higher progression in fibrotic ILAs; age did not affect progression once ILA was present.
- PFS estimates: 76% at 3 years and 55% at 5 years in 202 individuals with ILA.
Methodological Strengths
- Individual patient-level meta-analysis across global cohorts.
- Stratified analyses by age, sex, and smoking with progression and PFS estimates.
Limitations
- Heterogeneity in cohort designs and imaging protocols.
- Predominantly observational data; residual confounding possible.
Future Directions: Prospective validation of fibrotic-feature–based surveillance pathways and evaluation of interventions to slow progression in high-risk ILA.
RATIONALE: Interstitial lung abnormalities (ILA) are incidental CT findings that often represent early, subclinical interstitial lung disease. Their prevalence and progression rates vary widely across studies, emphasizing the need to understand the impact of age, sex, and smoking for better risk stratification and management. OBJECTIVES: To evaluate the prevalence and progression rates of ILA by age, sex, and smoking intensity using individual patient-level data from global cohorts, and to ana